Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors during the central nervous method, conolidine modulates alternate molecular targets. A Science Advancements study uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://henryj172mpv6.ltfblog.com/profile